Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Patient-reported adverse events associated with biologic therapies (with and without methotrexate), subcutaneous methotrexate, and oral methotrexate

From: Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis

AE, n (%) Biologics without MTX Biologics with MTX SQ MTX Oral MTX P value
n = 95 N = 123 n = 49 n = 115
Hair loss 10 (11) 11 (9) 17 (35) 35 (30) <0.0001
Diarrhea 2 (2) 6 (5) 6 (12) 26 (23) <0.0001
Vomiting 2 (2) 6 (5) 4 (8) 8 (7) 0.32
Nausea 11 (12) 17 (14) 27 (55) 39 (34) <0.0001
Other stomach problems 9 (10) 5 (4) 3 (6) 7 (6) 0.44
Fatigue 21 (22) 27 (22) 36 (73) 64 (56) <0.0001
Malaise 17 (18) 14 (11) 23 (47) 38 (33) <0.0001
Mental fog 14 (15) 19 (15) 18 (37) 33 (29) 0.0016
Infection 12 (13) 11 (9) 4 (8) 5 (4) 0.19
Any pain with injections 48a (89) 62a (84) 27 (55) N/A <0.0001
Side effect sumb      <0.0001
 0 67 (71) 91 (74) 5 (10) 36 (31)  
 1 4 (4) 7 (6) 9 (18) 12 (10)
 2 4 (4) 7 (6) 7 (14) 19 (17)
 3 10 (11) 5 (4) 12 (24) 17 (15)
 4 6 (6) 6 (5) 8 (16) 14 (12)
  > =5 4 (4) 7 (6) 8 (16) 17 (15)
  1. P values reported from chi-square test
  2. AE adverse event, MTX methotrexate, SQ subcutaneous
  3. aOf 128 patients who received biologic therapies subcutaneously
  4. bnumber of side effect of hair loss, diarrhea, vomiting, nausea, other stomach problems, fatigue, malaise, mental fog